Ruxolitinib sensitizes ovarian cancer to reduced dose Taxol, limits tumor growth and improves survival in immune competent mice.

Oncotarget · 2017 · PMC5706854 · PMID 29212208

Europe PMC DOI

hedged sentence

0.0684

closest p · 1.4× alpha

0.0684

boldest claim

The sentences

marginally significantp = 0.0684so close (0.05 < p ≤ 0.1)

Compared to Ruxo 30 alone, the increased survival in mice treated with a combination of Ruxo 30 and Taxol 10 was marginally significant (p = 0.0684), but was significant when compared to Taxol 10 treatment alone (p = 0.0158) and Ruxo 75 in combination with Taxol (p = 0.0204, Figure 5E ).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.